GLP-1 receptor agonists have gone from obscure diabetes medications to the most talked-about pharmaceutical category in the world in the span of a few years. Semaglutide, tirzepatide, and the emerging next-generation compound retatrutide are now household names. And the conversation around them is almost entirely wrong.

The mainstream narrative has collapsed into two equally useless positions. The first is uncritical enthusiasm — miracle drugs that effortlessly solve obesity, require no lifestyle change, and are appropriate for anyone who wants to lose weight. The second is dismissal — lazy shortcuts that produce the wrong kind of weight loss and destroy muscle. Both positions miss what these compounds actually are when used correctly.

GLPs are precision tools. In the right protocol, with the right foundation, the right dosing approach, and the right lifestyle running alongside them, they produce results that are genuinely remarkable. Without those things, they produce the muscle loss, metabolic disruption, and abandoned protocols that fuel the dismissal narrative. The difference is entirely in how they’re used.

The Wild West of GLP Prescribing

The prescribing and use of GLP-1 agonists is one of the clearest examples of a powerful tool being deployed without adequate framework. Clinics prescribing maximum doses from week one. Patients eating dramatically below maintenance because the hunger suppression is so effective that they simply stop feeling like eating. No guidance on protein targets. No requirement for resistance training. No discussion of gut motility management. No framework for what the protocol is actually supposed to accomplish.

The results of this approach are predictable. Rapid weight loss that looks impressive on a scale and looks concerning in the mirror — muscle loss alongside fat loss, a compromised metabolic rate, fatigue and performance decline from inadequate nutrition, and a protocol that gets abandoned because the side effects and results don’t match the promise. These are not GLP failures. They are protocol failures. The compound worked exactly as it was supposed to. Everything around it failed.

The Tempered approach to GLPs is the same as the Tempered approach to everything in Phase 3: precision, foundation first, conservative entry, deliberate progression, and honest monitoring over time.

What GLPs Actually Are and How They Work

GLP-1 (glucagon-like peptide-1) receptor agonists mimic a naturally occurring gut hormone that regulates blood sugar, gastric emptying, and appetite. The key mechanisms relevant to body composition and metabolic health:

Appetite and hunger regulation: GLP-1 agonists act on the hypothalamus to suppress hunger signals with a potency that most users find dramatic. This is the mechanism most people are familiar with but also the one most commonly mismanaged — effective hunger suppression requires deliberate nutrition management, not passive reliance on not feeling hungry.

Gastric emptying delay: Food moves through the stomach and digestive system more slowly, extending satiety and blunting post-meal blood sugar spikes. The practical consequence: gut motility slows significantly and requires active management.

Insulin sensitivity improvement: Independent of weight loss, GLP-1 agonists improve insulin sensitivity and glucose regulation. This nutrient partitioning effect means calories are used more efficiently — more goes to muscle and metabolism, less to fat storage.

Cardiovascular effects: Multiple large trials have shown meaningful reductions in major cardiovascular events, independent of weight loss. This is not a secondary benefit — for men over 40 with cardiovascular risk factors, the cardiac protection data alone warrants serious consideration.

Semaglutide, Tirzepatide, and Retatrutide

The three compounds worth understanding in the current landscape differ in mechanism and potency in ways that matter for protocol design.

Semaglutide: A GLP-1 receptor agonist. The original mainstream GLP compound. Well-established efficacy and safety profile from years of clinical use. The baseline against which newer compounds are measured.

Tirzepatide: A dual GIP and GLP-1 receptor agonist. Adding GIP (glucose-dependent insulinotropic polypeptide) agonism to GLP-1 produces meaningfully greater fat loss than semaglutide alone, with better preservation of lean mass in most head-to-head comparisons. The dual mechanism also tends to produce better tolerability at equivalent doses.

Retatrutide: A triple agonist hitting GLP-1, GIP, and glucagon receptors simultaneously. Still in late-stage trials but showing significantly greater fat loss than either semaglutide or tirzepatide, with favorable lean mass preservation data and additional metabolic benefits from glucagon receptor agonism including hepatic fat reduction. The most advanced compound in this category and the clearest direction the space is heading.

For men currently considering a GLP, tirzepatide’s combination of efficacy, tolerability, and established use makes it the current first-choice option for most protocols. Retatrutide is worth watching closely as it moves toward broader availability.

The Non-Negotiables: What Must Accompany GLP Use

These are not suggestions. They are the difference between a GLP protocol that produces the right outcome and one that produces the wrong one.

Hit your protein macro — every single day: The hunger suppression from GLPs is so effective that men stop eating enough without realizing it. Protein intake is the first casualty. Muscle loss follows. Set a timer and eat on schedule regardless of hunger level. Know your daily protein target and hit it deliberately, every day, whether you feel like eating or not. This is the single most important behavioral discipline in a GLP protocol.

Resistance train — non-negotiable: The studies showing muscle loss on GLPs are largely in populations not resistance training adequately. The studies showing preserved or improved lean mass are in populations who are. There is no version of a GLP protocol that produces good body composition outcomes without consistent resistance training. This is not optional.

Have your nutrition dialed in before you start: GLPs are not a substitute for nutritional discipline. They are a precision tool that amplifies the results of nutritional discipline already in place. A man who doesn’t have his nutrition sorted before starting a GLP will find that the hunger suppression makes it harder to eat correctly, not easier. Get the foundation right first.

Fiber and gut motility support: Gastric emptying delay compounds in the digestive system and constipation is one of the most common and most under-addressed side effects of GLP use. Adequate fiber, hydration, and motility support — magnesium is a practical dual-purpose option given its sleep and recovery benefits — are non-negotiable elements of protocol management.

Provider involvement: The wild west of GLP prescribing is not an argument against GLPs. It is an argument for finding a provider who treats this as precision medicine rather than a weight loss prescription. A provider who discusses protein targets, resistance training requirements, dose titration strategy, and gut motility management is running a real protocol. One who doesn’t is not.

Dosing: The Case for Starting Low and Going Slow

The standard clinic approach — ramping to maximum dose as quickly as tolerated — is one of the clearest wild west problems in GLP prescribing. The nausea, fatigue, and GI distress that give GLPs a bad reputation are largely dose-management failures, not compound failures. Peak concentration effects drive most of the early side effects, and aggressive titration amplifies those peaks unnecessarily.

The better approach: start at a conservative dose, allow the body to adapt, and titrate upward based on individual response and tolerance rather than a predetermined ramp schedule. The goal is the minimum effective dose that produces the desired metabolic effect — not the maximum dose the body can tolerate.

A related practical consideration: splitting the weekly dose into two or three smaller injections rather than a single weekly shot produces smoother blood levels and reduces the peak concentration effects that drive side effects. The formal trials use weekly dosing, but real-world experience suggests that more frequent, smaller doses improve tolerability and smooth out the hunger suppression curve in ways that make nutritional management more practical.

The Calorie Deficit Question

The instinct to combine aggressive caloric restriction with GLP use is understandable but counterproductive. A large caloric deficit on top of GLP-driven hunger suppression produces energy deficits that affect training performance, sleep quality, hormonal function, and recovery — the exact things that determine whether the weight being lost is fat or muscle.

The more effective approach is eating at maintenance or modest deficit and allowing the GLP’s effects on insulin sensitivity, nutrient partitioning, and metabolic efficiency to drive body composition change. The compound improves how the body uses the calories it receives — more to muscle and metabolism, less to fat. That effect does not require a steep deficit to activate.

The bodybuilding community has demonstrated this clearly. Elite athletes run GLP protocols in both cutting and bulking phases at very different calorie levels and achieve meaningful body composition improvements across all of them. The compound works at maintenance calories, deficit, and surplus. The partitioning effect is the mechanism, not the deficit.

Beyond Weight Loss: The Benefits Most People Don’t Know About

GLPs are almost universally framed as weight loss drugs. That framing undersells what the research actually shows by a significant margin.

Cardiovascular protection: The SUSTAIN and SURPASS trial data showed meaningful reductions in major cardiovascular events — heart attack, stroke, cardiovascular death — independent of weight loss. For men over 40 with any cardiovascular risk factors, this data alone warrants attention.

Neuroprotection and cognitive health: Emerging research on GLP-1 receptor agonists and neurodegeneration is genuinely compelling. Potential applications in Alzheimer’s and Parkinson’s disease are in active clinical investigation. The brain has GLP-1 receptors and they appear to matter for long-term cognitive health.

Liver health: NASH (non-alcoholic steatohepatitis) and hepatic fat reduction are well-documented GLP effects. For men with elevated liver enzymes or metabolic-associated liver disease, the hepatic benefits are direct and meaningful.

Addiction and compulsive behavior reduction: One of the most fascinating and least publicized GLP effects involves dopamine pathway modulation. Users consistently report reduced cravings not just for food but for alcohol, nicotine, and other compulsive behaviors. The mechanism involves GLP-1 receptors in the brain’s reward circuitry. Clinical research on addiction applications is active and early results are significant.

Inflammation reduction: Systemic anti-inflammatory effects independent of weight loss. For men whose inflammatory markers have been elevated, GLPs produce meaningful improvements that complement the lifestyle-driven changes from Phase 1 and 2.

Kidney protection: Emerging data on renal protection, particularly relevant for men with metabolic syndrome or early kidney function concerns.

GLPs are not weight loss drugs that happen to have other benefits. They are metabolic precision tools with a broad range of effects — weight loss being the most visible one.

FROM THE FIELD

I haven’t run GLPs personally. What I have is direct observation of people who have — done right and done wrong — and the contrast between those two experiences is more instructive than any clinical trial summary.

Done right: a woman with her foundation already built — training consistently, nutrition dialed in, high activity load. Three injections per week at a low starting dose, titrating up gradually. Calories slightly below maintenance. Hitting protein targets every day, deliberately, regardless of hunger. Layered retatrutide in later to amplify the effect. Went from 20% body fat to 14% in five months. Not aggressive, not dramatic week to week — slow, steady, and consistent. The results speak for themselves.

Done questionably: a man who started at a very high dose, one shot per week, with a very large caloric deficit alongside high training volume. The hunger suppression was so effective he couldn’t hit his macros. The large deficit destroyed his energy, performance, and sleep. By appearance he lost the wrong kind of weight — muscle alongside fat, leaving him smaller but not better. He abandoned the protocol. The GLP worked exactly as it was supposed to. Everything around it failed.

Both are N=1. But the pattern is consistent enough to be instructive. Slow and steady will outperform drastic and aggressive in this category exactly as it does in every other category in the Tempered framework. The compound is not the variable. The protocol is.

The Bottom Line

GLPs are legitimate precision tools with a broad and growing evidence base. Used correctly — foundation in place, protein non-negotiable, resistance training non-negotiable, conservative dosing, gut management in place, provider involved — they produce results that are genuinely remarkable and sustainable. Used incorrectly, they produce the muscle loss and abandoned protocols that define the wild west problem.

The Tempered approach applies here as it does everywhere: build the foundation first, add tools deliberately, start conservative, progress based on individual response, and measure over months not weeks. Slow and steady will always outperform drastic and short.

→ Phase 3 overview: Article 16 — The Second Peak

→ Lab work at Phase 3: Article 22 — Lab Work at Phase 3: Monitoring a Protocol (coming next)

→ Heart health and the cardiovascular stack: Article 23 — Heart Health: Tadalafil and the Cardiovascular Stack